1. Home
  2. GORO vs IPHA Comparison

GORO vs IPHA Comparison

Compare GORO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GORO

Gold Resource Corporation

HOLD

Current Price

$2.83

Market Cap

151.5M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$2.19

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GORO
IPHA
Founded
1998
1999
Country
United States
France
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.5M
165.3M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
GORO
IPHA
Price
$2.83
$2.19
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$1.63
$5.75
AVG Volume (30 Days)
1.8M
162.3K
Earning Date
05-07-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$25.99
$180.36
Revenue Next Year
$5.78
N/A
P/E Ratio
$70.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.44
$1.18
52 Week High
$4.00
$2.71

Technical Indicators

Market Signals
Indicator
GORO
IPHA
Relative Strength Index (RSI) 66.13 57.39
Support Level $0.84 $1.68
Resistance Level $4.00 $2.52
Average True Range (ATR) 0.21 0.12
MACD 0.03 0.05
Stochastic Oscillator 78.45 47.83

Price Performance

Historical Comparison
GORO
IPHA

About GORO Gold Resource Corporation

Goldgroup Mining Inc is focused on the acquisition, exploration and development of stage gold-bearing mineral properties in the Americas. The Companies current gold production and exploration and development related activities are conducted in Mexico. It property portfolio include Cerro Prieto project in Sonora and Pinos Project.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: